Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 37.42M 32.59M 30.84M 28.02M 52.35M 3.58B 52.61M 367M 142M 1.82B 141M 137M 5.83B P/E 2026 *
8.5x
P/E 2027 * -1.76x
Enterprise Value 37.42M 32.59M 30.84M 28.02M 52.35M 3.58B 52.61M 367M 142M 1.82B 141M 137M 5.83B EV / Sales 2026 *
3.21x
EV / Sales 2027 * -
Free-Float
90.17%
Yield 2026 *
-
Yield 2027 * -
08-15 Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program CI
08-15 Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug CI
08-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-30 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-30 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-09 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-23 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-23 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-07 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
1 day-4.03%
1 week-9.16%
Current month+16.67%
1 month+13.33%
3 months+16.67%
6 months+4.39%
Current year-12.50%
1 week 1.18
Extreme 1.18
1.42
1 month 0.97
Extreme 0.97
1.42
Current year 0.74
Extreme 0.735101
1.53
1 year 0.74
Extreme 0.735101
1.74
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26 Other

Chief Technology Officer

333,648 1.0634%
3/9/26 Other

Chief Technology Officer

403,868 1.2872%
2/9/26 Free

Director

157,000 0.5004%
Change 5-day change 1-year change 3-year change Capi.($)
-4.03%-9.16%-26.09%-81.91% 38.99M
+1.76%+3.88%+46.85%+101.12% 69.69B
+2.29%+1.43%+38.39%+77.03% 61.24B
+1.14%-2.59%-14.37%+365.92% 26.77B
+2.95%+2.34%+0.52%-12.74% 24.07B
+1.49%+7.73%+26.85%-15.89% 20.39B
-0.83%-9.47%+174.16%+295.44% 15.72B
+3.01%+1.85%+44.63%+168.18% 14.07B
+2.43%+4.24%-2.05%+847.59% 13.8B
+1.00%+0.24%+28.02%+203.83% 12.22B
Average +1.12%+0.67%+31.69%+194.86% 25.8B
Weighted average by Cap. +1.82%+1.73%+36.70%+163.27%

Financials

2026 *2027 *
Net sales 11.67M 10.16M 9.62M 8.74M 16.32M 1.12B 16.4M 115M 44.29M 568M 43.83M 42.85M 1.82B -
Net income 4.91M 4.27M 4.04M 3.67M 6.87M 470M 6.9M 48.18M 18.63M 239M 18.43M 18.02M 764M -31.71M -27.62M -26.14M -23.75M -44.36M -3.04B -44.58M -311M -120M -1.54B -119M -116M -4.94B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
17/09/26 US$1.190 -4.03% 57,023
16/09/26 US$1.240 -0.80% 59,768
15/09/26 US$1.250 -2.34% 96,168
14/09/26 US$1.280 -8.57% 301,511
11/09/26 US$1.400 +6.87% 242,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.190USD
Average target price
3.500USD
Spread / Average Target
+194.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!